Seres Therapeutics (MCRB) to Release Earnings on Tuesday

Seres Therapeutics (NASDAQ:MCRB) is anticipated to release its earnings data before the market opens on Tuesday, March 4th. Analysts expect Seres Therapeutics to post earnings of ($0.17) per share for the quarter.

Seres Therapeutics Stock Performance

Shares of MCRB stock opened at $0.79 on Tuesday. The stock’s fifty day moving average is $0.84 and its two-hundred day moving average is $0.85. The firm has a market capitalization of $134.80 million, a P/E ratio of -3.43 and a beta of 2.11. Seres Therapeutics has a fifty-two week low of $0.54 and a fifty-two week high of $1.53.

Analyst Ratings Changes

A number of brokerages have weighed in on MCRB. StockNews.com upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, February 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $10.00 target price on shares of Seres Therapeutics in a research note on Thursday, November 14th. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $1.25 target price on shares of Seres Therapeutics in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and an average target price of $5.08.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.